43285, RS,
Dihydrochloride, Ranolazine,
HCl, Ranolazine,
Hydrochloride, Ranolazine,
N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide,
Ranexa,
ranolazine,
Ranolazine Dihydrochloride,
Ranolazine HCl,
Ranolazine Hydrochloride,
renolazine,
RS 43285,
RS 43285 193,
RS 43285-193,
RS 43285193,
RS-43285,
RS43285,
Ranolazine dihydrochloride,
95635-56-6,
Ranolazine HCl,
Ranolazine 2HCl,
renolazine,
Ranolazine hydrochloride,
RS-43285,
N-(2,6-Dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide dihydrochloride,
RS 43285-193,
Ranolazine (dihydrochloride),
RS 43285,
Ranolazine hydrochloride [USAN],
MFCD03788770,
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide dihydrochloride,
(+-)-4-(2-Hydroxy-3-(o-methoxyphenoxy)propyl)-1-piperazineaceto-2',6'-xylidide dihydrochloride,
Ranolazine hydrochloride (USAN),
1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, dihydrochloride, (+-)-,
N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide dihydrochloride,
PubChem22105,
ra-nolazine hydrochloride,
AC1L2FVQ,
Ranolazine-dihydrochloride,
SCHEMBL230758,
C24H35Cl2N3O4,
CHEMBL1526084,
CTK8B4538,
RJNSNFZXAZXOFX-UHFFFAOYSA-N,
ACT06287,
BCP22680,
KS-00000XJ1,
Tox21_501062,
ANW-45416,
s1425,
AKOS015900516,
AC-3497,
API0004041,
CCG-222366,
CS-1130,
H35R555,
LP01062,
NCGC00094343-01,
NCGC00261747-01,
AN-12897,
BC215973,
HY-17401,
R463,
AB0007810,
AB2000098,
AX8215177,
LS-109923,
LS-172122,
TC-134161,
EU-0101062,
FT-0630989,
R0112,
ST24025537,
SW197620-3,
D05701,
R 6152,
W-5307,
RS 43285-193;RS-43285;Ranexa;renolazine,
A845356,
C-22941,
I14-0738,
Ranolazine dihydrochloride, >=98% (HPLC), powder,
SR-01000076216-2,
N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy),
() -4-[2-Hydroxy-3-(o-methoxyphenoxy)propyl]-1-piperazineaceto-2',6'-xylidide dihydrochloride,
1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine 2HCl,
1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine dihydrochloride salt,
N-(2,6-Dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)-propyl)piperazin-1-yl)acetamide dihydrochloride,
N-(2,6-Dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide dihydroch,
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazinyl]acetamide dihydrochloride,
N-(2,6-dimethylphenyl)-2-[4-[3-(2-methoxyphenoxy)-2-oxidanyl-propyl]piperazin-1-yl]ethanamide dihydrochloride,
propyl]-1-piperazineacetamide dihydrochloride; ( inverted question mark) -4-[2-hydroxy-3-(o-methoxyphenoxy)propyl]-1-piperazineaceto-2',6'-xylidide dihydrochloride,
Ranexa,
RANOLAZINE,
HCl, Ranolazine,
Ranolazinedihydrochloride,
Hydrochloride, Ranolazine,
UNII-F71253DJUN,
Dihydrochloride, Ranolazine,
C24H33N3O4.2ClH,
F71253DJUN,
CID71279,
C24-H33-N3-O4.2Cl-H,
ACN-034427,
CS-O-11732,
RS43285,
43285, RS,
95635-56-6 (HCl),
RS 43285193,
RS 43285 193,
SR-01000076216,
D000069458,
95635-55-5,
N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide,
Ranolazine dihydrochloride, 98%, an anti-ischemic agent - 1G 1g,